Evidence map›Paper›PMID 40730910›Full record

ReviewNature microbiology2025

Evolution of antifungal resistance in the environment.

Norman van Rhijn, Johanna Rhodes

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Climate change and antimicrobial resistance.Nature reviews. Microbiology · 2026
    Review
  8. Article
  9. Repurposing FDA-Approved Drugs to Inhibit Fungal PPTases for Broad-Spectrum Synergy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  10. Article
  11. Article
  12. Review
  13. Innovation in antifungal therapy.EMBO molecular medicine · 2026
    Review
  14. Article
  15. Article
  16. Article
  17. Genotype-Phenotype Relationships in Azole-ResistantJournal of fungi (Basel, Switzerland) · 2026
    Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Norman van RhijnManchester Fungal Infection Group, Division of Evolution, Infection and Genomic Science, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. norman.vanrhijn@manchester.ac.uk.ORCID http://orcid.org/0000-0001-6722-2757
Johanna RhodesDepartment of Medical Microbiology, Radboudumc, the Netherlands. johanna.rhodes@radboudumc.nl.ORCID http://orcid.org/0000-0002-1338-7860

Funding

Wellcome Trust (Wellcome) 219551/Z/19/ZWellcome Trust (Wellcome) 226408/Z/22/Z
6 · The paper itself

Abstract

The emergence of drug-resistant fungal infections in agriculture and healthcare settings has caused severe implications for food security, public health and natural environments. They pose a substantial hazard for at-risk patient populations who often acquire serious and sometimes life-threatening infections. With the increasing use of fungicides in the environment, acquisition of resistance to fungicides and antifungal drugs pose a risk to health. In this Review we summarize the evolution, emergence and expansion of fungicide and antifungal drug resistance globally. We discuss different antifungals and fungicides, their modes of action and resistance mechanisms. Furthermore, we outline the current state of knowledge about the emergence and expansion of resistant fungi in hotspots and coldspots in the environment. Finally, we summarize alternative options and future directions in reducing antifungal resistance.

Indexed as

Antifungal AgentsDrug Resistance, FungalEnvironmental MicrobiologyFungiFungicides, IndustrialHumansMycosesAntifungal AgentsFungicides, Industrial

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.